SCHEMBL16292274

SCHEMBL16292274

N#C/C(=C\c1ccc(-c2cccc(C(=O)O)c2)o1)c1ccccc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 7/20 0.55
▸ TDP1 Q9NUW8 5/20 0.55
▸ KDM4E B2RXH2 4/20 0.55
▸ ALDH1A1 P00352 4/20 0.55
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ MAPT P10636 7/20 0.51
▸ MEN1 O00255 4/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ RECQL P46063 2/20 0.51
▸ APEX1 P27695 1/20 0.51
▸ SAE1 Q9UBE0 1/20 0.51
▸ UBA2 Q9UBT2 1/20 0.51
▸ LDHA P00338 2/20 0.49
▸ LMNA P02545 3/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.48
▸ HPGD P15428 2/20 0.48
▸ HTT P42858 1/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16292278 1.00 POLB (0.55) POLBTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL16292277 1.00 POLB (0.55) POLBTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL16291420 0.76 MEN1 (0.86) POLBTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL16291419 0.76 MEN1 (0.86) POLBTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL6721359 0.76 MAPT (0.81) POLBTDP1KDM4EALDH1A1MAPT
SCHEMBL16291421 0.76 MEN1 (0.86) POLBTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL2554180 0.72 POLB (1.00) POLBTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL26168420 0.69 ALDH1A1 (0.72) POLBTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL26168424 0.67 ALDH1A1 (0.70) POLBTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL31358664 0.67 PIM1 (0.72) POLBTDP1KDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10633369-B2 Method of inhibiting DYRK1B 4 SC AG (DE) 2020-04-28 — — US disclosed
US-20180201606-A1 METHOD OF INHIBITING DYRK1B 4 SC AG (DE) 2018-07-19 — — US disclosed
US-9951050-B2 Method of inhibiting DYRK1B 4 SC AG (DE) 2018-04-24 — — US disclosed
US-20140371251-A1 METHOD OF INHIBITING DYRK1B 4SC DISCOVERY GMBH (DE) 2014-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10633369-B2 Method of inhibiting DYRK1B SMO, GLI1, GRK2 POLB 3039/4885TDP1 3140/4885KDM4E 996/4885
US-20180201606-A1 METHOD OF INHIBITING DYRK1B SMO, GLI1, GRK2 POLB 3039/4885TDP1 3140/4885KDM4E 996/4885
US-20140371251-A1 METHOD OF INHIBITING DYRK1B SMO, GLI1, GRK2 POLB 3039/4885TDP1 3140/4885KDM4E 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback